Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status.

The aim of the present study was to evaluate the possible influence of oral opioids, pain and performance status on some aspects of psychomotor function and cognition in cancer patients. One hundred and thirty cancer patients between 40 and 76 years of age were consecutively included in the study. In order to separate the impact of performance status, pain and oral opioids on neuropsychological functioning the patients were allocated in a cross-sectional design to five different groups. Group 1 (N=40), which was considered the control group, was characterized by being in Karnofsky Performance Status (KPS) A ('Able to carry on normal activity and work. No special care is needed'), had no pain and received no oral opioid medication. Group 2 (N=19) was characterized by being in KPS B ('Unable to work. Able to live at home and care for most personal needs. A varying degree of assistance is needed'), had no pain and received no oral opioid medication. Group 3 (N=19) was characterized by being in KPS B, had pain, but received no oral opioid medication. Group 4a (N=31) was characterized by being in KPS B, had pain and received stable doses of oral opioids. Group 4b (N=21) was characterized by being in KPS B, had no pain and received stable doses of opioids. Assessments comprised pain intensity, sedation, opioid doses, time from ingestion of last opioid dose to testing and opioid side effects. The neuropsychological tests used were continuous reaction time (CRT), finger tapping test (FTT) and paced auditory serial addition task (PASAT). Regarding the neuropsychological tests group 1 was compared with each of the other groups and respecting the hierarchy of increasing numbers of stigmatizing factors group 1 was compared with group 2, group 2 with group 3 and so forth. Concerning CRT, group 1 performed statistically significantly faster than groups 2, 4a and 4b. Concerning FTT, group 1 performed statistically significantly faster than groups 3 and 4a. Concerning PASAT, groups 1 and 4b performed statistically significantly better than group 4a. Furthermore, the pain-relieved groups 2 and 4b performed statistically significantly better in PASAT than the pain-suffering groups 3 and 4a. We conclude that in cancer patients the impact of stigmatizing factors (oral opioids, pain and reduced performance status) seems to impair some important aspects of neuropsychological performance, but more specifically our results indicate that (1) the use of long-term oral opioid treatment in cancer patients per se did not affect any of the neuropsychological tests used in the present study, (2) cancer patients being in KPS B had statistically significantly slower CRT than patients being in KPS A and (3) pain itself may deteriorate the performance of PASAT more than oral opioid treatment.

Colorectal cancer in the Faroe Islands--a setting for the study of the role of diet.

BACKGROUND: The Faroe Islands are a group of small islands in the north Atlantic. The population is well-defined and is therefore very suitable for epidemiological research, including dietary studies in relation to carcinogenesis. With the establishment of a cancer registry on January 1, 1994, with data from 1960, inspection of incidence rates and trends in cancer may give clues to areas for etiologic research. METHODS: We identified retrospectively all incident cases of colorectal cancer in the period 1979-1993, by reviewing all case reports and death certificates in the Faroe Islands. RESULTS: We found 242 cases of colorectal cancer: 166 colon cancers and 76 rectal cancer, of which 93% and 96% (respectively) were histologically confirmed. Colorectal cancer incidence was significantly lower than in Denmark, with standardised incidence ratios (SIRs) for colon cancer at 0.8 (95% CI = 0.7-1.0) in men and 0.7 (95% CI = 0.6-0.9) in women. For rectal cancer SIRs were 0.6 (95% CI = 0.5-0.9) in males and 0.6 (95% CI = 0.4-0.9) in females. CONCLUSIONS: This paper presents for the first time incidence rates of colorectal cancer in the Faroe Islands. For both cancer types the most recent standardised incidence rates, 1989-1993, were among the lowest in north western Europe and North America. This relatively low risk of colorectal cancer occurs in spite of a low intake of vegetables and a high intake of total fat. However, the Faroese diet is high in fish, calcium and vitamin D and the possibility therefore exist that the low rates are due to a protective effect of these nutrients and micronutrients.

[Cancer registration in the Faeroe Islands]. / Cancerregistrering på Faerøerne.

The main purpose was to establish a cancer registry which could provide data for the treatment and control of cancer in the Faroe Islands. The registry should also be useful for epidemiological research in the future to pinpoint causes of cancer. The initiation of the registry is a result of a workgroup with members from the Faroes Hospital and Health System and from the Institute of Cancer Epidemiology at the Danish Cancer Society. The data items collected in the Faroes registry are identical with the data items in the Danish Cancer Registry. To provide a basis for the registry we have performed a retrospective data collection identifying all cancer cases in the Faroes for the 15 year period 1979-1993. All hospital records and death certificates in the period were scrutinized. The official initiation of the Faroes cancer registry was on 1, January 1994.

High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands.

We have examined the incidence of non-AIDS-related Kaposi's sarcoma in Iceland (1955-79) and the Faroe Islands (1974-95). In Iceland, 19 cases, nine in men and ten in women, were identified, and in the Faroe Islands four cases in men and three cases in women were found. This corresponded to surprisingly high incidence rates. In men, world standardized rates (per 100000 person-years) were 0.4 and 0.6 in Iceland and the Faroe Islands, respectively, and for women, the figures were 0.3 (Iceland) and 0.5 (the Faroe Islands). These are among the highest rates ever reported. No explanation for the high rates of Kaposi's sarcoma in these two North Atlantic communities could be identified.